Metformin and the risk of dementia based on an analysis of 396,332 participants.

ABSTRACT:

Background

AMPK has attracted widespread interest as a potential therapeutic target for age-related diseases, given its key role in controlling energy homeostasis. Metformin (Met) has historically been used to treat Type 2 diabetes and has been shown to counteract age-related diseases. However, studies regarding the relationship between Met and a variety of age-related classifications of cognitive decline have reported mixed findings.

Objective

To assess the potential effect of Met on the onset of dementia and discuss the possible biological mechanisms involved.

Methods

This study was registered in the PROSPERO database (CRD420201251468). PubMed, Embase, and Cochrane Library were searched from inception to 25 May 2021, for population-based cohort studies. Effect estim

SUBMITTER: Ji S 

PROVIDER: S-EPMC9277541 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature